The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

Due to the risk of rebound congestion (known by some as rhinitis medicamentosa or nasal spray addiction), over-the-counter decongestant medication such as Afrin should not be used for more than three ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.

Cipla Ltd. has expressed optimism about exceeding its FY25 guidance, supported by strong operational performance and a focused strategy. The company stated that supply challenges related to Lanreotide ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...